Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2010

01.12.2010 | Brief Communication

A Complete Response in Small Cell Carcinoma of the Esophagus Treated by S-1/Cisplatin Combined Chemotherapy and Radiotherapy

verfasst von: Masatsugu Hiraki, Masayuki Tanaka, Seiji Sato, Keita Kai, Kiyoto Morito, Kiichiro Kobayashi, Hirokazu Noshiro, Osamu Tokunaga, Kohji Miyazaki

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Small cell carcinoma of the esophagus (SmCCE) is a rare disease which is considered to be more malignant than the most common types of esophageal cancer. The optimal treatment strategy for this disease still remains controversial. A 69-year-old male was diagnosed to have SmCCE (stage IIIA, T3N1M0). Due to the patient’s poor general condition, chemo-radiotherapy consisting of S-1/cisplatin therapy and a total of 60 Gy of radiotherapy was performed. After the treatment, the main lesion completely disappeared while some ulceration remained. A histological examination revealed no viable cancer cells in biopsy specimens obtained by endoscopy. Computed tomographic examinations showed a decreased wall thickness of the esophagus and an improvement in the swelling of the lymph nodes. S-1 monotherapy was administered following the main chemoradiation therapy, and it was performed for a total of 20 courses. The patient has been doing well without recurrence for over 3 years. We judged the effect to be a complete response. This combination chemo-radiotherapy with S-1 and cisplatin may therefore be one of the effective treatments against SmCCE.
Literatur
2.
Zurück zum Zitat Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, et al. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistoghemical features of 21 cases. BMC Cancer. 2007;7:38. doi:10.1186/1471-2407-7-38.CrossRefPubMed Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, et al. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistoghemical features of 21 cases. BMC Cancer. 2007;7:38. doi:10.​1186/​1471-2407-7-38.CrossRefPubMed
4.
Zurück zum Zitat Koide N, Saito H, Suzuki A, Sato T, Koiwai K, Nakamura N, et al. Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus. J Gastroenterol. 2007;42:932–8. doi:10.1007/s00535-007-2114-0.CrossRefPubMed Koide N, Saito H, Suzuki A, Sato T, Koiwai K, Nakamura N, et al. Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus. J Gastroenterol. 2007;42:932–8. doi:10.​1007/​s00535-007-2114-0.CrossRefPubMed
5.
Zurück zum Zitat Beyer KL, Marshall JB, Diaz-Arias AA, Loy TS. Primary small-cell carcinoma of the esophagus. Report of 11 cases and review of the literature. J Clin Gastroenterol. 1991;13:135–41.CrossRefPubMed Beyer KL, Marshall JB, Diaz-Arias AA, Loy TS. Primary small-cell carcinoma of the esophagus. Report of 11 cases and review of the literature. J Clin Gastroenterol. 1991;13:135–41.CrossRefPubMed
7.
Zurück zum Zitat Sun KL, He J, Cheng GY, Chai LX. Management of primary small cell carcinoma of the esophagus. Chin Med J (Engl). 2007;120:355–8. Sun KL, He J, Cheng GY, Chai LX. Management of primary small cell carcinoma of the esophagus. Chin Med J (Engl). 2007;120:355–8.
10.
Zurück zum Zitat Hosokawa A, Shimada Y, Matsumura Y, Yamada Y, Muro K, Hamaguchi T, et al. Small cell carcinoma of the esophagus. Analysis of 14 cases and literature review. Hepatogastroenterology. 2005;52:1738–41.PubMed Hosokawa A, Shimada Y, Matsumura Y, Yamada Y, Muro K, Hamaguchi T, et al. Small cell carcinoma of the esophagus. Analysis of 14 cases and literature review. Hepatogastroenterology. 2005;52:1738–41.PubMed
11.
12.
Zurück zum Zitat Chin K, Baba S, Hosaka H, Ishiyama A, Mizunuma N, Shinozaki E, et al. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Jpn J Clin Ooncol. 2008;38:426–31. doi:10.1093/jjco/hyn041.CrossRef Chin K, Baba S, Hosaka H, Ishiyama A, Mizunuma N, Shinozaki E, et al. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Jpn J Clin Ooncol. 2008;38:426–31. doi:10.​1093/​jjco/​hyn041.CrossRef
13.
Zurück zum Zitat Matsuoka M, Boku N, Yoshino T, Hironaka S, Onozawa Y, Fukutomi A, et al. Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel. Int J Clin Oncol. 2005;10:429–32. doi:10.1007/s10147-005-0502-0.CrossRefPubMed Matsuoka M, Boku N, Yoshino T, Hironaka S, Onozawa Y, Fukutomi A, et al. Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel. Int J Clin Oncol. 2005;10:429–32. doi:10.​1007/​s10147-005-0502-0.CrossRefPubMed
14.
Zurück zum Zitat Bibeau F, Chateau MC, Guiu M, Assenat E, Azria D, Lavaill R, et al. Small cell carcinoma with concomitant adenocarcinoma arising in a Barett’s oesophagus: report of a case with a favourable behaviour. Virchows Arch. 2008;452:103–7. doi:10.1007/s00428-007-0533-1.CrossRefPubMed Bibeau F, Chateau MC, Guiu M, Assenat E, Azria D, Lavaill R, et al. Small cell carcinoma with concomitant adenocarcinoma arising in a Barett’s oesophagus: report of a case with a favourable behaviour. Virchows Arch. 2008;452:103–7. doi:10.​1007/​s00428-007-0533-1.CrossRefPubMed
15.
Zurück zum Zitat Sobin L, Gospodarowicz M, Wittekind C, editors (2009) TNM classification of malignant tumors, 7th edn. UICC International Union Against Cancer Sobin L, Gospodarowicz M, Wittekind C, editors (2009) TNM classification of malignant tumors, 7th edn. UICC International Union Against Cancer
16.
Zurück zum Zitat U.S. Department of Health and Human Services (2009) Common terminology criteria for adverse event (CTCAE), version 4.0. National Institutes of Health, National Cancer Institute. U.S. Department of Health and Human Services (2009) Common terminology criteria for adverse event (CTCAE), version 4.0. National Institutes of Health, National Cancer Institute.
18.
Zurück zum Zitat Medgyesy CD, Wolff RA, Putnam Jr JB, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000;88:262–7.CrossRefPubMed Medgyesy CD, Wolff RA, Putnam Jr JB, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000;88:262–7.CrossRefPubMed
21.
Zurück zum Zitat Lam KY, Law S, Tung PH, Wong J. Esophageal small cell carcinomas: clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis. Arch Pathol Lab Med. 2000;124:228–33.PubMed Lam KY, Law S, Tung PH, Wong J. Esophageal small cell carcinomas: clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis. Arch Pathol Lab Med. 2000;124:228–33.PubMed
23.
Zurück zum Zitat Lara Jr PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–5. doi:10.1200/JCO.2008.20.1061.CrossRefPubMed Lara Jr PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–5. doi:10.​1200/​JCO.​2008.​20.​1061.CrossRefPubMed
24.
Zurück zum Zitat Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30:23–36. doi:10.1016/S0169-5002(00)00127-6.CrossRefPubMed Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30:23–36. doi:10.​1016/​S0169-5002(00)00127-6.CrossRefPubMed
25.
Zurück zum Zitat Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur–0.4 M 5-chloro-2,4-dihydroxypyridine–1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602–6.PubMed Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur–0.4 M 5-chloro-2,4-dihydroxypyridine–1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602–6.PubMed
26.
27.
Zurück zum Zitat Sakaguchi Y, Kabashima A, Okita K, Ojima Y, Yamamura S, Nishizaki T, et al. Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. Gastric Cancer. 2005;8:111–6. doi:10.1007/s10120-004-0313-4.CrossRefPubMed Sakaguchi Y, Kabashima A, Okita K, Ojima Y, Yamamura S, Nishizaki T, et al. Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. Gastric Cancer. 2005;8:111–6. doi:10.​1007/​s10120-004-0313-4.CrossRefPubMed
29.
Zurück zum Zitat Iwase H, Indo T, Shimada M, Tsuzuki T, Nakarai K, Kaida S, et al. Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin. Int J Clin Oncol. 2004;9:398–402. doi:10.1007/s10147-004-0412-6.CrossRefPubMed Iwase H, Indo T, Shimada M, Tsuzuki T, Nakarai K, Kaida S, et al. Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin. Int J Clin Oncol. 2004;9:398–402. doi:10.​1007/​s10147-004-0412-6.CrossRefPubMed
30.
Zurück zum Zitat Hiraki M, Yunotani S, Noguchi R, Shinozaki Y, Tani H, Sakai M, et al. Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy. Jpn J Cancer Chemotherapy. 2005;32:219–21. Hiraki M, Yunotani S, Noguchi R, Shinozaki Y, Tani H, Sakai M, et al. Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy. Jpn J Cancer Chemotherapy. 2005;32:219–21.
31.
Metadaten
Titel
A Complete Response in Small Cell Carcinoma of the Esophagus Treated by S-1/Cisplatin Combined Chemotherapy and Radiotherapy
verfasst von
Masatsugu Hiraki
Masayuki Tanaka
Seiji Sato
Keita Kai
Kiyoto Morito
Kiichiro Kobayashi
Hirokazu Noshiro
Osamu Tokunaga
Kohji Miyazaki
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2010
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9159-7

Weitere Artikel der Ausgabe 4/2010

Journal of Gastrointestinal Cancer 4/2010 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.